Zynex (NASDAQ:ZYXI) Issues Quarterly Earnings Results

Zynex (NASDAQ:ZYXI) posted its earnings results on Tuesday. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.09 by ($0.11), Zacks reports. Zynex had a return on equity of 13.05% and a net margin of 2.49%. During the same quarter in the prior year, the firm posted $0.04 EPS. Zynex updated its Q1 2025 guidance to -0.300- EPS.

Zynex Trading Down 2.4 %

NASDAQ:ZYXI opened at $7.00 on Wednesday. Zynex has a 12 month low of $4.36 and a 12 month high of $13.19. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66. The firm’s 50 day moving average is $7.72 and its 200 day moving average is $8.02. The stock has a market capitalization of $222.92 million, a PE ratio of 46.67 and a beta of 0.81.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. LADENBURG THALM/SH SH lowered Zynex from a “buy” rating to a “neutral” rating in a report on Wednesday. Royal Bank of Canada lowered Zynex from an “outperform” rating to a “sector perform” rating and decreased their target price for the company from $11.00 to $5.50 in a research report on Wednesday. Finally, HC Wainwright cut their price target on shares of Zynex from $17.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday.

Insider Buying and Selling at Zynex

In other news, CFO Daniel J. Moorhead sold 10,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $7.68, for a total transaction of $76,800.00. Following the completion of the transaction, the chief financial officer now owns 19,738 shares in the company, valued at approximately $151,587.84. This represents a 33.63 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 30,000 shares of company stock valued at $227,100. Company insiders own 52.13% of the company’s stock.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.